Economic Cost of Age-Related Macular Degeneration: A Review of Recent Research
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
As the population of most developed countries ages so the prevalence of diseases such as age-related macular degeneration (AMD) are likely to increase. To facilitate planning and informed debate regarding making provisions for this disease it is important that we have a clear understanding of the economic impact of visual impairment associated with AMD. In this paper we assess the state of current knowledge based on a review of published evidence in scientific journals. Based on our assessment of the evidence we argue that the paucity of research studies on the subject and wide variation in estimates produced from the few studies available make it difficult to assess with confidence the likely average direct cost-of-illness associated with AMD. We further argue that significant gaps in our understanding of the costs of AMD (particularly in respect of indirect costs) also exist. Current research should be augmented by more comprehensive studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The searches were restricted to English language journal articles published after 1 st January, 2000 to better reflect current practices and prices which were in large part influenced by the advent of certain technologies, such as anti-VEGFs in the mid-2000s [22, 25].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [25]
Citations
Cites
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Global data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157
Risk factors for age-related macular degeneration
Smith, W., Assink, J., Klein, R., Mitchell, P., Klaver, C. C. W., Klein, B. E. K., Hofman, A., Jensen, S., Wang, J. J., & de Jong, P. T. V. M. (2001) · Ophthalmology · doi:10.1016/s0161-6420(00)00580-7 · Cited by 1,071
Methods for the economic evaluation of health care programmes, 3rd ed
Adamiak, G. T. (2006) · PubMed Central · Cited by 953
Brody, B. L., Gamst, A. C., Williams, R. A., Smith, A. R., Lau, P. W., Dolnak, D., Rapaport, M. H., Kaplan, R. M., & Brown, S. I. (2001) · Ophthalmology · doi:10.1016/s0161-6420(01)00754-0 · Cited by 581
Richer, S., Stiles, W., Statkute, L., Pulido, J., Frankowski, J., Rudy, D., Pei, K., Tsipursky, M., & Nyland, J. (2004) · Optometry - Journal of the American Optometric Association · doi:10.1016/s1529-1839(04)70049-4 · Cited by 566
The Psychosocial Impact of Macular Degeneration
Williams, R. A. (1998) · Archives of Ophthalmology · doi:10.1001/archopht.116.4.514 · Cited by 423
Age-Related Macular Degeneration
Fine, S. L., Berger, J. W., Maguire, M. G., & Ho, A. C. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002173420707 · Cited by 418
Brown, G. C. (1999) · Europe PMC (PubMed Central) · Cited by 368
Research works printed but not linked: 3
- Resnikoff, 2004, Bull World Health Organ, 82, 844
- Husereau, 2002, Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 31, 40
- Brown, 1999, Trans Am Ophthalmol Soc, 97, 473
Cited by
Age-Related Macular Degeneration: Role of Oxidative Stress and Blood Vessels
Ruan, Y., Jiang, S., & Gericke, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031296 · Cited by 178
Azad, R., Chandra, P., & Gupta, R. (2007) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.36479 · Cited by 53
Economic Burden of Late-Stage Age-Related Macular Degeneration in Bulgaria, Germany, and the US
Paudel, N., Brady, L., Stratieva, P., Galvin, O., Lui, B., Brande, I. V. D., Malkowski, J., Rebeira, M., MacAllister, S., O’Riordan, T., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.4401 · Cited by 44
Minassian, D. C., & Reidy, A. (2009) · Cited by 44
Ke, K. M. (2010) · The European Journal of Health Economics · doi:10.1007/s10198-009-0207-9 · Cited by 25
Self-citation
Metadata
- Authors
- Ke, K. M., Chakravarthy, U., & O???Neill, C.
- Affiliations
- Queen's University Belfast (GB)
- ORCID
- Chakravarthy, Usha
- Venue
- Drugs & Aging
- Published
- 2006
- Volume
- 23
- Issue
- 3
- Pages
- 217-225
- ISSN
- 1170-229X (ISSN-L)
- OpenAlex
- W2017811645
- Cited by
- 12
- References
- 34
- Citations by year
- 2025: 2 · 2024: 2 · 2022: 1 · 2021: 1 · 2013: 2
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs & Aging (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Visual Impairment Studies
- Keywords
- age-related macular degeneration, economic cost of illness, direct costs, indirect costs, visual impairment, cost estimate
- MeSH terms
- Aged, Aging, Cost-Benefit Analysis, Costs and Cost Analysis, Health Planning, Humans, Macular Degeneration, Databases, Bibliographic, Health Care Costs, Cost of Illness, Models, Economic, Biomedical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Economic Cost of Age-Related Macular Degeneration: A Review of Recent Research. https://app.cochat.ai/papers/10.2165/00002512-200623030-00004
- The paper
- Ke, K. M., Chakravarthy, U., & O???Neill, C. (2006). Economic Cost of Age-Related Macular Degeneration: A Review of Recent Research. Drugs & Aging. https://doi.org/10.2165/00002512-200623030-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.